In vitro characterization of chitosan gels for buccal delivery of celecoxib: Influence of a penetration enhancer

AAPS PharmSciTech

Volumn 13, Issue 1, 2012, Pages 101-111

  Cid, Yara Peluso ^a   Pedrazzi, Vinícius ^b   De Sousa, Valéria Pereira ^a   Pierre, Maria Bernadete Riemma ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Azone; Buccal mucosa; Celecoxib; Chitosan; In vitro permeability; In vitro release; Mucoadhesion; Rheology

Indexed keywords

CELECOXIB; CHITOSAN; LAUROCAPRAM; PENETRATION ENHANCING AGENT;

ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; FLOW KINETICS; IN VITRO STUDY; MUCOADHESION; NONHUMAN; PH; PRIORITY JOURNAL; SWINE; VISCOSITY;

ADMINISTRATION, BUCCAL; ANIMALS; CHITOSAN; DRUG DELIVERY SYSTEMS; GELS; MOUTH MUCOSA; PERMEABILITY; PYRAZOLES; SULFONAMIDES; SWINE;

EID: 84861092301     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9725-8     Document Type: Article

References (52)

1. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum. 1998;31:1591-602.
2. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M. A selective cyclooxygenase-2 inhibitor suppress tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res. 1999;90:1152-62.
3. Wang Z, Fluentes CF, Shapshay SM. Anti-angiogenic and chemopreventive activities in oral carcinoma cell. Laryngoscope. 2002;112:839-43. (Pubitemid 34477613)
4. Wang Z, Polavaram R, Shapshay SM. Topical inhibition of oral carcinoma cell with polymer delivered celecoxib. Cancer Lett. 2003;198:53-8. (Pubitemid 37289103)
5. Crowelli JA. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview. Eur J Cancer. 2005;41:1889-910.
6. Lippman SM. The future of molecular-target cancer chemoprevention. Gastroenterology. 2008;135:1834-41.
7. Kemal Kismet M, Turan Akay M, Osman Abbasoglu, Aygün Ercan MD. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Canc Detect Prev. 2004;28:127-42. (Pubitemid 38448751)
8. Sood S, Shiff SJ. Selection of topically applied no-steroidal antiinflammatory drugs for oral cancer chemoprevention. Oral Oncol. 2006;41:562-7. (Pubitemid 40828872)
9. Méric JB, Rottey S. Cyclooxyxenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol. 2006;59:51-64. (Pubitemid 43903278)
10. Papadimitrakopoulou V, Hon WK. Retinoids in head and neck chemoprevention. Proc Soc Exp Biol Med. 1997;216:283-90.
11. Ventura CA, Giannone I, Paolino D, Pistarà V, Corsaro A, Puglisi G. Preparation of celecoxib-dimethyl-b-cyclodextrin inclusion complex: characterization and in vitro permeation study. Eur J Med Chem. 2005;40:624-31. (Pubitemid 40797558)
12. Ventura CA, Tommasini S, Falcone A, Giannone I, Paolino D, Sdrafkakis V, et al. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin. Int J Pharm. 2006;314(1):37-45.
13. Remuñán-López C, Portero A, Vila-Jato JL, Alonso MJ. Design and evaluation of chitosan/ethylcellulose mucoadhesive bilayer devices for buccal drug delivery. J Contr Release. 1998;55:143-52. (Pubitemid 28477605)
14. Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev. 2005;57:1666-91. (Pubitemid 41443474)
15. Sandri G, Rossi S, Ferrari F, Bomferoni MC. Assessment of chitosan derivates as buccal and vaginal penetration enhancers. Eur J Pharm Sci. 2004;21:351-9. (Pubitemid 38156173)
16. Obara CK, Ishihara M, Ozeki Y, Ishizuka T. Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice. J Contr Release. 2005;110:79-89. (Pubitemid 41713933)
17. Martin L, Wilson CG, Koosh F. Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels. Eur J Pharm Biopharm. 2003;55:35-45. (Pubitemid 36120493)
18. He P, Davis SS, Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm. 1998;166:75-88. (Pubitemid 28239741)
19. Nicolazzo JA, Reed BL, Finnin BC. Buccal penetration enhancers: how do they really work? J Contr Release. 2005;105:1-115.
20. Nicolazzo JA, Reed BLJ. Enhanced buccal mucosal retention and reduced buccal permeability of estradiol in the presence of padimate O and Azone: a mechanistic study. Pharm Sci. 2005;94:873-82. (Pubitemid 40577319)
21. Nicolazzo JA, Reed BL, Finnin BC. Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide. J Contr Release. 2005;105:240-8. (Pubitemid 40941989)
22. Senel S, Kremer MJ, Kas S. Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials. 2000;21:2067-71. (Pubitemid 30488077)
23. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivates. Adv Drug Deliv Rev. 2001;52:117-26. (Pubitemid 33079167)
24. Moreira TS, Cid YP, Pierre MBR, Kummerle AE, Fraga CAM, Sousa VP. Extração e purificação de fármacos antiinflamatórios não esteroidais ciclooxigenase-2 seletivos. Química Nova. 2009;32:1324-8.
25. Moreira TS, Sousa VP, Pierre MBR. A novel transdermal delivery system for the anti-inflammatory lumiracoxib: influence of oleic acid on in vitro percutaneous absorption and in vivo potential cutaneous irritation. AAPS PharmSciTech. 2010;11:621-9.
26. Ravi Kumar MNV. A review of chitin and chitosan applications. React Funct Polym. 2000;46:1-27. (Pubitemid 33763425)
27. Sokker HH, Abdel Ghaffar AM, Gad YH. Synthesis and characterization of hydrogels based on grafted chitosan for the controlled drug release. Carbohyd Polym. 2009;75:222-9.
28. Corrêa NM, Camargo Jr FB, Ignácio RF, Leonardi GR. Avaliação do comportamento reológico de diferentes géis hidrofílicos. Rev Bras Cienc Farm. 2005;41:73-8.
29. Anchisi C. Physical properties of chitosan dispersions in glycolic acid. Il farmaco. 2004;59:557-61. (Pubitemid 38844813)
30. Perioli L, Pagano C, Mazzitelli S. Rheological and functional characterization of new antiinflammatory delivery systems designed for buccal administration. Int J Pharm. 2008;356:18-28.
31. Barry BW. Recent advanced in pharmaceutical rheology. J Texture Stud. 2007;1:405-30.
32. Lee CH, Moturi V, Lee Y. Thixotropic property in pharmaceutical formulations. J Contr Release. 2009;136:88-98.
33. Williams AC, Barry BW. Permeation enhancers. Adv Drug Deliv Rev. 2004;56:603-18.
34. Aksungur P, Sungur A, Unal S, Iskit AB, Squier CA, Senel S. Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies. J Contr Release. 2004;98:269-79. (Pubitemid 38950736)
35. Rossi S, Marciello M, Bonferoni MC, Ferrari F, Sandri G, Dacarro C, et al. Thermally sensitive gels based on chitosan derivatives for the treatment of oral mucositis. Eur J Pharm Biopharm. 2010;74:248-54.
36. Heemstra LB, Finnin BC, Nicolazzo JA. The buccal mucosa as an alternative route for the systemic delivery of risperidone. J Pharm Sci. 2010;99(11):4584-92.
37. Sandri G, Rossi S, Bonferoni MC. Buccal penetration enhancement properties of N-trimethyl chitosan: influence of quaternization degree on absorption of a high molecular weight molecule. Int J Pharm. 2005;297:146-55. (Pubitemid 40720274)
38. Rossi S, Ferrari F, Bonferoni MC, Caramella C. Characterization of chitosan hydrochloride-mucin interaction bymeans of viscosimetric and turbidimetric measurements. Eur J Pharm Sci. 2000;10:251-7. (Pubitemid 30317460)
39. Kremer MJ, Squier CA, Wertz PW. Absorption and release of topical triamcinolone in oral mucosa. J Dent Res. 1997;76:361.
40. Squier CA, Kremer MJ, Bruskin A, Rose A, Haley JD. Oral mucosal permeability and stability of transforming growth factor beta-3 in vitro. Pharm Res. 1999;16:1557-63. (Pubitemid 29510552)
41. Hassan N, Ahad A, Ali M, Ali J. Chemical permeation enhancers for transbuccal drug delivery. Expet Opin Drug Deliv. 2010;7:97-112.
42. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm. 2001;51:93-109. (Pubitemid 32162488)
43. Stoughton RB. Enhanced percutaneous absorption with 1- dodecylazacycloheptan-2-one (Azone). Arch Dermatol. 1982;118:474-7. (Pubitemid 12078111)
44. Lashmar UT, Hadgraft J, Thomas N. Topical application of penetration enhancers to the skin of nude mice: a histopathological study. J Pharm Pharmacol. 1989;41:118-21.
45. Fang J, Hwang T, Fang C, Chiu H. In vitro and in vivo evaluations of the efficacy and safety of skin permeation enhancers using flurbiprofen as a model drug. Int J Pharm. 2003;255:153-66. (Pubitemid 36369599)
46. Van Hoogdalem EJ, Vermeij-Kerrs C, De Boer AG, Breimer DD. Topical effects of absorption enhancing agents on the rectal mucosa of rats in vivo. J Pharm Sci. 1990;79:866-70. (Pubitemid 20362807)
47. Durand-Cavagna G, Duprat P, Molon-Noblot S, Delort P, Rozier A. Corneal endothelial changes with azone, a penetration enhancer. Lens Eye Toxic Res. 1989;6:109-17. (Pubitemid 19227060)
48. Ismail IM, Chen C, Richman JB, Andersen JS, Tang-Liu DD. Comparison of azone and hexamethylene lauramide in toxicologic effects and penetration enhancement of cimetidine in rabbit eyes. Pharm Res. 1992;9:817-21.
49. López-Cervantes M, Márquez-Mejía E, Cázares-Delgadillo J, Quintanar-Guerrero D, Ganem-Quintanar A, Ángeles-Anguiano E. Chemical enhancers for the absorption of substances through the skin: laurocapramand its derivatives. Drug Dev Ind Pharm. 2006;32 (3):267-86.
50. Parikh DK, Ghosh TK. Feasibility of transdermal delivery of fluoxetine. AAPS PharmSciTech. 2005;6(2):E114-49.
51. Ahad A, Aqil M, Kohli K, Chaudhary H, Sultana Y, Mujeeb M, et al. Chemical penetration enhancers: a patent review. Expert Opin Ther Pat. 2009;19(7):969-88.
52. Perioli L, Ambrogi V, Venezia L, Pagano C, Ricci M, Rossi C. Chitosan and a modified chitosan as agents to improve performances of mucoadhesive vaginal gels. Colloids Surf B Biointerfaces. 2008;66:141-5.